Evaluation of a New Concentrate for the Treatment of Factor IX Deficiency

Abstract

A commercially prepared plasma concentrate was administered in six infusions to four patients with factor IX deficiency. All showed a distinct rise in the factor IX level. On the basis of the preliminary data a dose of 2 factor IX units per kilogram of body weight could be expected to produce a 1 percent rise in the factor IX level. Larger doses may be necessary in the actively bleeding patient. No serious side effects were observed. The increased factor IX concentration and the relatively low protein content of the material greatly reduces the possibility of precipitating circulatory overload while still achieving hemostatic factor IX levels.